Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK2110183 Gelatin Capsule
GSK2110183 Gelatin · 1 trial · 1 indication
PK parameters include: area under the plasma concentration-time curve from time zero to infinity (AUC \[0-infinity\]), area under the plasma concentration time curve from time zero to last time of quantifiable concentration (AUC \[0-t\]), maximum observed plasma concentration (Cmax), and time to Cmax (tmax).
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC |
| Sequence 2 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB |
| Sequence 3 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC |
| Sequence 4 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA |
| Sequence 5 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB |
| Sequence 6 | EXPERIMENTAL | Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA |
| Name | Type | Description |
|---|---|---|
| GSK2110183 Gelatin Capsule | DRUG | White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration |
| GSK2110183 IR Tablet | DRUG | White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration |
Inclusion Criteria: * Provided signed written informed consent * Healthy Male or female between 18 and 40 years of age inclusive, at the time the informed consent is obtained. * Body weight \>=50 kilograms (kg) and body mass index (BMI) of \>=18 and \<= 32 kg/meter square (m\^2). * A female subject...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
GSK2110183 Gelatin is an investigational small molecule formulation of GSK2110183 developed by GSK plc for use in cancer. It is a gelatin capsule form studied in a Phase 1 bioavailability and food effect trial. It is also known as GSK2110183 Gelatin Capsule.
GSK2110183 Gelatin is being studied in cancer, within the oncology therapeutic area. Its only recorded clinical trial enrolled healthy adult volunteers to assess the bioavailability and food effect of the gelatin formulation compared with an immediate release tablet formulation of afuresertib.
GSK2110183 Gelatin is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 bioavailability and food effect study of the gelatin formulation and the immediate release tablet formulation of afuresertib.
GSK2110183 Gelatin is in Phase 1 development. It is investigational and has not been approved for any indication. The single recorded trial, NCT02040480, is a completed Phase 1 study with 18 enrolled participants conducted in Australia.
GSK2110183 Gelatin has been studied in one clinical trial, NCT02040480, titled Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib. It was a completed Phase 1 controlled study with 18 participants, conducted in Australia in healthy volunteers aged 18 years and older.
Yes, GSK2110183 Gelatin and GSK2110183 Gelatin Capsule refer to the same investigational product from GSK plc. The capsule name describes the gelatin capsule dosage form studied in the Phase 1 bioavailability and food effect trial NCT02040480.